This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Pacific Biosciences Hurt by Competition in Niche Markets
by Zacks Equity Research
Pacific Biosciences (PACB) faces cutthroat competition in the niche space. Also, sluggishness in the European markets is a concern.
Top Research Reports for Microsoft, Intel & UnitedHealth
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Intel (INTC) and UnitedHealth (UNH).
Thermo Fisher Buys Phenom-World, Aids Analytical Instruments
by Zacks Equity Research
On completion of Phenom-World purchase, Thermo Fisher (TMO) plans to integrate the business into its Analytical Instruments segment.
Can AngioDynamics (ANGO) Pull a Surprise in Q2 Earnings?
by Zacks Equity Research
AngioDynamics (ANGO) to gain from solid product portfolio and demand for Solero MTA system. However, unfavorable estimates are a concern.
Global In Vitro Diagnostic Market Booms: Stocks in Focus
by Zacks Equity Research
With the emergence of complex and transmittable diseases worldwide, In Vitro Diagnostic within the MedTech space is currently in the spotlight.
IDEXX Laboratories (IDXX) Q3 Earnings Beat, Revenues Miss
by Zacks Equity Research
IDEXX Laboratories (IDXX) rides high on strength in Companion Animal Group business in Q3. Moreover, a raised guidance buoys optimism.
Luminex (LMNX) Tops Q3 Earnings, Meets Revenue Estimates
by Zacks Equity Research
Luminex's (LMNX) third quarter saw a strong top line, solid cash flow as well as profits in Q3. The company's Assay business is likely to drive growth over the long term.
Thermo Fisher (TMO) Q3 Earnings & Sales Top, Guidance Up
by Zacks Equity Research
On solid third-quarter performance, a favorable foreign exchange environment and the recently closed acquisition of Patheon, Thermo Fisher (TMO) has raised its full-year 2017 guidance.
Thermo Fisher (TMO) Beats on Q3 Earnings & Sales Estimates
by Zacks Equity Research
Thermo Fisher (TMO) rides high in Q3 banking on its analytical instruments segment in particular.
MedTech Stocks (BAX, VAR, TMO, LH) Earnings Preview: What You Should Know
by Zacks Equity Research
The Medical Product space has been a precarious game for the Republicans since day one, courtesy of President Trump's repeated failure to repeal and replace Obamacare.
PetMed (PETS) Tops Q2 Earnings & Sales Estimates, Margins Up
by Zacks Equity Research
The year-over-year rise in earnings of PetMed (PETS) was driven by an increase in sales and improved margins.
Will S.E.T. Arm Drive Zimmer Biomet's (ZBH) Q3 Earnings?
by Zacks Equity Research
Zimmer Biomet (ZBH) poised to gain on strength in S.E.T as well as Spine & CMF segments in Q3.
Why Thermo Fisher (TMO) Might Surprise This Earnings Season
by Zacks Equity Research
Thermo Fisher (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Henry Schein (HSIC) Q3 Earnings to Show Growth in All Lines
by Zacks Equity Research
Henry Schein (HSIC) likely to gain on strength across all business segments in Q3.
What's in Store for Penumbra (PEN) Stock in Q3 Earnings?
by Zacks Equity Research
Penumbra (PEN) is expected to gain from strong performance by its neuro and peripheral vascular arms in Q3.
Can Companion Animal Group Drive IDEXX's (IDXX) Q3 Earnings?
by Zacks Equity Research
IDEXX Laboratories (IDXX) is poised to gain from strength in its Companion Animal Group business in Q3.
Will Invisalign Drive Align Technology's (ALGN) Q3 Earnings?
by Zacks Equity Research
Align Technology (ALGN) is poised to gain from strength in the Invisalign space in Q3.
Will GNC Holdings (GNC) Disappoint This Earnings Season?
by Zacks Equity Research
Revenue growth at GNC Holdings (GNC) might remain sluggish on declining sales of protein, vitamins, weight management and food and drink categories in Q3.
Quest Diagnostics (DGX) Beats Earnings in Q3, Updates View
by Zacks Equity Research
Despite hurricanes related financial impact, Quest Diagnostics (DGX) posted year-over-year growth in Q3 on recent acquisitions, tie-ups and strength in several advanced diagnostic offerings.
Varian Medical (VAR) Initiates Halcyon Treatment in Europe
by Zacks Equity Research
Varian (VAR) has been taking initiatives to gain customers for its broad spectrum of products, especially targeting emerging markets.
Abbott (ABT) Exceeds Q3 Earnings, '17 Guidance Narrowed
by Zacks Equity Research
Abbott (ABT) posted promising Q3 results primarily on the back of strong EPD sales and emerging market expansion.
Will Recall Issue Hurt Boston Scientific (BSX) Q3 Earnings?
by Zacks Equity Research
Although Boston Scientific's (BSX) recent $435-million acquisition of Symetis SA might drive its IC business, the company's full recovery post a primary product recall may however, take time.
What to Expect From Thermo Fisher (TMO) in Q3 Earnings
by Zacks Equity Research
Thermo Fisher (TMO) gears up for another quarter of strong analytical instruments segmental growth. Improvement is likely to be seen in applied markets too.
Phibro Animal Banks on Diverse Portfolio, Competition Rife
by Zacks Equity Research
Phibro Animal (PAHC) is consistently trying to expand its product portfolio to counter the tough competition in the animal health space.
Henry Schein (HSIC) Inks Distribution Agreement with Terason
by Zacks Equity Research
Henry Schein's (HSIC) distribution agreement with Terason to distribute the latter's uSmart 3200T NexGen is likely to boost its global Medical segment business.